BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19836372)

  • 21. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
    Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Necroptosis: a novel therapeutic target for glioblastoma.
    Jiang YG; Peng Y; Koussougbo KS
    Med Hypotheses; 2011 Mar; 76(3):350-2. PubMed ID: 21075544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging EGFR therapies for glioblastoma.
    Artene SA; Tuţă C; Dragoi A; Alexandru O; Stefana Oana P; Tache DE; Dănciulescu MM; Boldeanu MV; Siloşi CA; Dricu A
    J Immunoassay Immunochem; 2018; 39(1):1-11. PubMed ID: 29308973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines.
    Mégalizzi V; Decaestecker C; Debeir O; Spiegl-Kreinecker S; Berger W; Lefranc F; Kast RE; Kiss R
    Eur J Cancer; 2009 Nov; 45(16):2893-905. PubMed ID: 19679463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges.
    Nicholas MK; Lukas RV; Chmura S; Yamini B; Lesniak M; Pytel P
    Semin Oncol; 2011 Apr; 38(2):243-53. PubMed ID: 21421114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frontiers in targeting glioma stem cells.
    Frosina G
    Eur J Cancer; 2011 Mar; 47(4):496-507. PubMed ID: 21185169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
    Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
    Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel treatment for glioblastoma: integrin inhibition.
    Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
    Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.
    Suwala AK; Hanaford A; Kahlert UD; Maciaczyk J
    J Neuropathol Exp Neurol; 2016 May; 75(5):388-96. PubMed ID: 26979081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
    Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
    Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.
    Loew S; Schmidt U; Unterberg A; Halatsch ME
    Anticancer Agents Med Chem; 2009 Jul; 9(6):703-15. PubMed ID: 19601750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
    Westphal M; Maire CL; Lamszus K
    CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastoma: therapeutic challenges, what lies ahead.
    Lima FR; Kahn SA; Soletti RC; Biasoli D; Alves T; da Fonseca AC; Garcia C; Romão L; Brito J; Holanda-Afonso R; Faria J; Borges H; Moura-Neto V
    Biochim Biophys Acta; 2012 Dec; 1826(2):338-49. PubMed ID: 22677165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies.
    Agnihotri S; Burrell KE; Wolf A; Jalali S; Hawkins C; Rutka JT; Zadeh G
    Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):25-41. PubMed ID: 23224339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taking advantage of neural development to treat glioblastoma.
    Zhang Z; Lin CC
    Eur J Neurosci; 2014 Sep; 40(6):2859-66. PubMed ID: 24964151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Glioblastoma, an example of translational research?].
    Kroonen J; Nguyen-Khac MT; Deprez M; Rogister B; Robe P
    Rev Med Liege; 2008; 63(5-6):251-6. PubMed ID: 18669189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic strategies to target multiple kinases in glioblastoma.
    Sathornsumetee S
    Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule tyrosine kinase inhibitors in glioblastoma.
    Kim G; Ko YT
    Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.